Characterization of Structural p53 Mutants Which Show Selective Defects in Apoptosis but Not Cell Cycle Arrest

REFERENCES

• Antonsson, B., F. Conti, A. Ciavatta, S. Montessuit, S. Lewis, I. Martinou, L. Bernasconi, A. Bernard, J.-J. Mermod, G. Maxxei, K. Maundrell, F. Gambale, R. Sadoul, and J.-C. Martinou 1997. Inhibition of Bax channel-forming activity by Bcl-2. Science 277: 370–372.
   PubMed Web of Science ®Google Scholar
• Bates, S., and K. H. Vousden 1996. p53 in signalling checkpoint arrest or apoptosis. Curr. Opin. Genet. Dev. 6: 1–7.
   PubMedGoogle Scholar
• Brugarolas, J., C. Chandrasekaran, J. I. Gordon, D. Beach, T. Jacks, and G. J. Hannon 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 552–556.
   PubMed Web of Science ®Google Scholar
• Buckbinder, L., R. Talbott, S. Velasco-Miguel, I. Takenaka, B. Faha, B. R. Seizinger, and N. Kley 1995. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377: 646–649.
   PubMed Web of Science ®Google Scholar
• Caelles, C., A. Helmberg, and M. Karin 1994. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370: 220–223.
   PubMed Web of Science ®Google Scholar
• Chen, X., L. J. Ko, L. Jayaraman, and C. Prives 1996. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10: 2438–2451.
   PubMed Web of Science ®Google Scholar
• Cho, Y., S. Gorina, P. D. Jeffery, and N. P. Pavletich 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346–355.
   PubMed Web of Science ®Google Scholar
• Crook, T., C. Fisher, P. J. Masterson, and K. H. Vousden 1994. Modulation of transcriptional regulatory properties of p53 by HPV E6. Oncogene 9: 1225–1230.
   PubMedGoogle Scholar
• Crook, T., N. J. Marston, E. A. Sara, and K. H. Vousden 1994. Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 79: 817–827.
   PubMedGoogle Scholar
• Delia, D., K. Goi, S. Mizutani, T. Yamada, A. Aiello, E. Fontanella, G. Lamorte, S. Iwata, C. Ishioka, S. Krajewski, J. C. Reed, and M. A. Pierotti 1997. Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations. Oncogene 14: 2137–2147.
   PubMedGoogle Scholar
• Deng, C., P. Zhang, J. W. Harper, S. J. Elledge, and P. Leder 1995. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675–684.
   PubMed Web of Science ®Google Scholar
• Di Leonardo, A., S. P. Linke, K. Clarkin, and G. M. Wahl 1994. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 8: 2540–2551.
   PubMed Web of Science ®Google Scholar
• Friedlander, P., Y. Haupt, C. Prives, and M. Oren 1996. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol. Cell. Biol. 16: 4961–4971.
   PubMed Web of Science ®Google Scholar
• Ginsberg, D., F. Mechta, M. Yaniv, and M. Oren 1991. Wild type p53 can down-modulate the activity of various promoters. Proc. Natl. Acad. Sci. USA 88: 9979–9983.
   PubMed Web of Science ®Google Scholar
• Haupt, Y., R. Maya, A. Kazaz, and M. Oren 1997. Mdm2 promotes the rapid degradation of p53. Nature 387: 296–299.
   PubMed Web of Science ®Google Scholar
• Haupt, Y., S. Rowan, E. Shaulian, K. H. Vousden, and M. Oren 1995. Induction of apoptosis in HeLa cells by trans-activation deficient p53. Genes Dev. 9: 2170–2183.
   PubMed Web of Science ®Google Scholar
• Hollstein, M., K. Rice, M. S. Greenblatt, T. Soussi, R. Fuchs, T. Sørlie, E. Hovig, B. Smith-Sørensen, R. Montesano, and C. C. Harris 1994. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22: 3551–3555.
   PubMed Web of Science ®Google Scholar
• Kim, E., N. Albrechtsen, and W. Deppert 1997. DNA-conformation is an important determinant of sequence-specific DNA binding by tumor suppressor p53. Oncogene 15: 857–869.
   PubMed Web of Science ®Google Scholar
• Knudson, M. C., K. S. K. Tung, W. G. Tourtellotte, G. A. J. Brown, and S. J. Korsmeyer 1995. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 270: 96–98.
   PubMed Web of Science ®Google Scholar
• Ko, L. J., and C. Prives 1996. p53: puzzle and paradigm. Genes Dev. 10: 1054–1072.
   PubMed Web of Science ®Google Scholar
• Kubbutat, M. H. G., S. N. Jones, and K. H. Vousden 1997. Regulation of p53 stability by Mdm2. Nature 387: 299–303.
   PubMed Web of Science ®Google Scholar
• Lam, E. W. F., and R. J. Waston 1993. An E2F-binding site mediates cell-cycle regulation repression of mouse B-myb transcription. EMBO J. 12: 2705–2713.
   PubMed Web of Science ®Google Scholar
• Lane, D. P. 1992. p53, guardian of the genome. Nature 358: 15–16.
   PubMed Web of Science ®Google Scholar
• Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88: 323–331.
   PubMed Web of Science ®Google Scholar
• Lowe, S. W., H. E. Ruley, T. Jacks, and D. E. Housman 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957–967.
   PubMed Web of Science ®Google Scholar
• Ludwig, R. L., S. Bates, and K. H. Vousden 1996. Differential transcriptional activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol. Cell. Biol. 16: 4952–4960.
   PubMed Web of Science ®Google Scholar
• Mack, D. H., J. Vartikar, J. M. Pipas, and L. A. Laimins 1993. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature 363: 281–283.
   PubMed Web of Science ®Google Scholar
• McCurrach, M. E., T. M. F. Connor, M. C. Knudson, S. J. Korsmeyer, and S. W. Lowe 1997. bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc. Natl. Acad. Sci. USA 94: 2345–2349.
   PubMed Web of Science ®Google Scholar
• Miyashita, T., and J. C. Reed 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293–299.
   PubMed Web of Science ®Google Scholar
• Momand, J., G. P. Zambetti, D. L. George, and A. J. Levine 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237–1245.
   PubMed Web of Science ®Google Scholar
• Murphy, M., A. Hinman, and A. J. Levine 1996. Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev. 10: 2971–2980.
   PubMed Web of Science ®Google Scholar
• Ory, K., Y. Legros, C. Auguin, and T. Soussi 1994. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J. 13: 3496–3504.
   PubMed Web of Science ®Google Scholar
• Pietenpol, J. A., T. Tokino, S. Thiagaligam, W. El-Deiry, K. W. Kinzler, and B. Vogelstein 1994. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl. Acad. Sci. USA 91: 1998–2002.
   PubMed Web of Science ®Google Scholar
• Polyak, K., T. Waldman, T.-C. He, K. W. Kinzler, and B. Vogelstein 1996. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev. 10: 1945–1952.
   PubMed Web of Science ®Google Scholar
• Rowan, S., R. L. Ludwig, Y. Haupt, S. Bates, X. Lu, M. Oren, and K. H. Vousden 1996. Specific loss of apoptotic but not cell cycle arrest function in a human tumour derived p53 mutant. EMBO J. 15: 827–838.
   PubMed Web of Science ®Google Scholar
• Sabbatini, P., S.-K. Chiou, L. Rao, and E. White 1995. Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein. Mol. Cell. Biol. 15: 1060–1070.
   PubMedGoogle Scholar
• Shen, Y. Q., and T. Shenk 1994. Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular bcl-2 protein. Proc. Natl. Acad. Sci. USA 91: 8940–8944.
   PubMedGoogle Scholar
• Subler, M. A., D. W. Martin, and S. Deb 1992. Inhibition of viral and cellular promoters by human wild-type p53. J. Virol. 66: 4757–4762.
   PubMedGoogle Scholar
• Symonds, H., L. Krall, L. Remington, M. Saenzrobles, S. Lowe, T. Jacks, and T. Van Dyke 1994. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78: 703–711.
   PubMed Web of Science ®Google Scholar
• Treisman, R. 1986. Identification of a protein-binding site that mediates transcriptional response of the c-fos gene to serum factors. Cell 46: 567–574.
   PubMed Web of Science ®Google Scholar
• Wagner, A. J., J. M. Kokontis, and N. Hay 1994. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes Dev. 8: 2817–2830.
   PubMed Web of Science ®Google Scholar
• Waldman, T., K. W. Kinzler, and B. Vogelstein 1995. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55: 5187–5190.
   PubMed Web of Science ®Google Scholar
• Yin, C., C. M. Knudson, S. J. Korsmeyer, and T. Van Dyke 1997. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385: 637–640.
   PubMed Web of Science ®Google Scholar